Therapeutic agents triggering nonapoptotic cancer cell death

Journal of Medicinal Chemistry

Volumn 56, Issue 12, 2013, Pages 4823-4839

  Kornienko, Alexander ^a   Mathieu, Véronique ^b   Rastogi, Shiva K ^a   Lefranc, Florence ^c   Kiss, Robert ^b  

^a Texas State University   (United States)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 4877; BROMOCRIPTINE; CHALCONE DERIVATIVE; CHLOROQUINE; CILENGITIDE; DZ 50; EVEROLIMUS; FENRETINIDE; FUROQUINOLINE; GADOLINIUM TEXAPHYRIN; GINSENOSIDE; GOSSYPOL; GUANIDINE; HONOKIOL; IHI 062; IMIDAZOACRIDONE; INIPARIB; ISOSORBIDE; ISPINESIB; JSM 6427; KAHALALIDE F; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; OBATOCLAX; PODOPHYLLOTOXIN; RAPAMYCIN; RUCAPARIB; SHIKONIN; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; VELIPARIB;

ANCHORAGE INDEPENDENT GROWTH; ANOIKIS; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; BRAIN CANCER; CANCER CELL; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DEATH; DRUG BINDING; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; G2 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; LUNG METASTASIS; LYSOSOMAL MEMBRANE PERMEABILIZATION; MELANOMA; METASTASIS INHIBITION; MITOSIS; NECROPTOSIS; OXIDATIVE STRESS; PARAPTOSIS; PARTHANATOS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL DEATH; HUMANS; LYSOSOMES; NEOPLASMS;

EID: 84879584721     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400136m     Document Type: Review

References (137)

1. Howlader, N.; Noone, A. M.; Krapcho, M.; Neyman, N.; Aminou, R.; Waldron, W. SEER Cancer Statistics Review, 1975-2008; National Cancer Institute: Bethesda, MD, 2011.
2. Gordon, R. R.; Nelson, P. S. Cellular senescence and cancer chemotherapy resistance Drug Resist. Updates 2012, 15, 123-131
3. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics Ca-Cancer J. Clin. 2011, 61, 69-90
4. Lefranc, F.; Brotchi, J.; Kiss, R. Possible future issues in the treatment of glioblastomas, with a special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis J. Clin. Oncol. 2005, 23, 2411-2422
5. Soengas, M. S.; Lowe, S. W. Apoptosis and melanoma chemoresistance Oncogene 2003, 22, 3138-3151
6. Kennedy, B.; Gargoum, F.; Bystricky, B. R.; Curran, D. M.; O'Connor, T. Novel agents in the management of lung cancer Curr. Med. Chem. 2010, 17, 4291-4325
7. Bruyère, C.; Lonez, C.; Duray, A.; Cludts, S.; Ruysschaert, J. M.; Saussez, S.; Yeaton, P.; Kiss, R.; Mijatovic, T. Considering temozolomide as a novel potential treatment for oesophageal cancer Cancer 2011, 117, 2004-2016
8. Wong, H. H.; Lemoine, N. R. Pancreatic cancer: molecular pathogenesis and new therapeutic targets Nat. Rev. Gastroenterol. Hepatol 2009, 6, 412-422
9. Bussink, J.; van Herpen, C.; Kaanders, J.; Oyen, W. PET-CT for response assessment and treatment adaptation in head and neck cancer Lancet Oncol. 2010, 11, 661-669
10. Simpson, C. D.; Anyiwe, K.; Schimmer, A. D. Anoikis resistance and tumor metastasis Cancer Lett. 2008, 272, 177-185
11. Chiarugi, P.; Giannoni, E. Anoikis: a necessary death program for anchorage-dependent cells Biochem. Pharmacol. 2008, 76, 1352-1364
12. Galluzzi, L.; Vitale, I.; Abrams, J. M.; Alnemri, E. S.; Baehrecke, E. H.; Blagosklonny, M. V.; Dawson, T. M.; Dawson, V. L.; El-Deiry, W. S.; Fulda, S.; Gottlieb, E.; Green, D. R.; Hengartner, M. O.; Kepp, O.; Knight, R. A.; Kumar, S.; Lipton, S. A.; Lu, X.; Madeo, F.; Malorni, W.; Mehlen, P.; Nunez, G.; Peter, M. E.; Piacentini, M.; Rubinsztein, D. C.; Shi, Y.; Simon, H. U.; Vandenabeele, P.; White, E.; Yuan, J.; Zhivotovsky, B.; Melino, G.; Kroemer, G. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012 Cell Death Differ. 2012, 19, 107-120
13. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer Nat. Rev. Drug Discovery 2006, 5, 219-234
14. Hall, M. D.; Handley, M. D.; Gottesman, M. M. Is resistance useless? Multidrug resistance and collateral sensitivity Trends Pharmacol. Sci. 2009, 30, 546-556
15. Malam, Y.; Loizidou, M.; Seifalian, A. M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer Trends Pharmacol. Sci. 2009, 30, 592-599
16. Fletcher, J. I.; Haber, M.; Henderson, M. J.; Norris, M. D. ABC transporters in cancer: more than just efflux pumps Nat. Rev. Cancer 2010, 10, 147-156
17. Ni Chonghaile, T.; Sarosiek, K. A.; Vo, T. T.; Ryan, J. A.; Tammareddi, A.; Moore, V. D. G.; Deng, J.; Anderson, K.; Richardson, P.; Tai, Y. T.; Mitsiades, C. S.; Matulonis, U. A.; Drapkin, R.; Stone, R.; DeAngelo, D. J.; McConkey, D. J.; Sallan, S. E.; Silverman, L.; Hirsch, M. S.; Carrasco, D. R.; Letai, A. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy Science 2011, 334, 1129-1133
18. +-ATPase to combat chemoresistant cancers Curr. Med. Chem. 2012, 19, 627-646
19. Rosenzweig, S. A. Acquired resistance to drugs targeting receptor tyrosine kinases Biochem. Pharmacol. 2012, 83, 1041-1048
20. Wilson, T. R.; Fridlyand, J.; Yan, Y.; Penuel, E.; Burton, L.; Chan, E.; Peng, J.; Lin, E.; Wang, Y.; Sosman, J.; Ribas, A.; Li, J.; Moffat, J.; Sutherlin, D. P.; Koeppen, H.; Merchant, M.; Neve, R.; Settleman, J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Nature 2012, 487, 505-509
21. Cotter, T. G. Apoptosis and cancer: the genesis of a research field Nat. Rev. Cancer 2009, 9, 501-507
22. Giansanti, V.; Tillhon, M.; Mazzini, G.; Prosperi, E.; Lombardi, P.; Scovassi, A. I. Killing of tumor cells: a drama in two acts Biochem. Pharmacol. 2011, 82, 1304-1310
23. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144, 646-674
24. Indran, I. R.; Tufo, G.; Pervaiz, S.; Brenner, C. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells Biochim. Biophys. Acta 2011, 1807, 735-745
25. Kreuzaler, P.; Watson, C. J. Killing a cancer: What are the alternatives? Nat. Rev. Cancer 2012, 12, 411-424
26. Demers, M.; Krause, D. S.; Schatzberg, D.; Martinod, K.; Voorhees, J. R.; Fuchs, T. A.; Scadden, D. T.; Wagner, D. D. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 13076-13081
27. Zhou, Y.; Cheng, Y.; Feng, D.; Ling, B.; Liu, P. Induction the cornification of squamous cancerous cells to eliminate tumor cells by promotion cell differentiation and stratum Med. Hypotheses 2011, 77, 763-764
28. Wan, Q.; Liu, J.; Zheng, Z.; Zhu, H.; Chu, X.; Dong, Z.; Huang, S.; Du, Q. Regulation of myosin activation during cell-cell contact formation by Par3-LgI antagonism: entosis without matrix detachment Mol. Biol. Cell 2012, 23, 2076-2091
29. Overholtzer, M.; Mailleux, A. A.; Mouneimne, G.; Normand, G.; Schnitt, S. J.; King, R. W.; Cibas, E. S.; Brugge, J. S. A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion Cell 2007, 131, 966-979
30. Brennan, M. A.; Cookson, B. T. Salmonella induces macrophage death by caspase-1-dependent necrosis Mol. Microbiol. 2000, 38, 31-40
31. Bergsbaken, T.; Fink, S. L.; Cookson, B. T. Pyroptosis: host cell death and inflammation Nat. Rev. Microbiol. 2009, 7, 99-109
32. Kepp, O.; Galluzzi, L.; Zitvogel, L.; Kroemer, G. Pyroptosis-a cell death modality of its kind? Eur. J. Immunol. 2010, 40, 627-630
33. Taddei, M. L.; Giannoni, E.; Fiaschi, T.; Chiarugi, P. Anoikis: an emerging hallmark in health and diseases J. Pathol. 2012, 226, 380-393
34. Nagaprashantha, L.; Vartak, N.; Awasthi, S.; Awasthi, S.; Singhal, S. S. Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors Pharm. Res. 2012, 29, 621-636
35. Cox, D.; Brennan, M.; Moran, N. Integrins as therapeutic targets: lessons and opportunities Nat. Rev. Drug Discovery 2010, 9, 804-820
36. Svensen, N.; Walton, J. G.; Bradley, M. Peptides for cell-selective drug delivery Trends Pharmacol. Sci. 2012, 33, 186-192
37. Kurozumi, K.; Ichikawa, T.; Onishi, M.; Fujii, K.; Date, I. Cilengitide treatment for malignant glioma: current status and future direction Neurol. Med. Chir. 2012, 52, 539-547
38. Gilbert, M. R.; Kuhn, J.; Lamborn, K. R.; Lieberman, F.; Wen, P. Y.; Mehta, M.; Cloughesy, T.; Lassman, A. B.; DeAngelis, L. M.; Chang, S.; Prados, M. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery J. Neuro-Oncol. 2012, 106, 147-153
39. Wang, W.; Wang, F.; Lu, F.; Xu, S.; Hu, W.; Huang, J.; Gu, Q.; Sun, X. The antiangiogenic effects of integrin alpha 5 beta 1 inhibitor (ATN-161) in vitro and in vivo Invest. Ophthalmol. Visual Sci. 2011, 52, 7213-7220
40. Doñate, F.; Parry, G. C.; Shaked, Y.; Hensley, H.; Guan, X.; Beck, I.; Tel-Tsur, Z.; Plunkett, M. L.; Manuia, M.; Shaw, D. E.; Kerbel, R. S.; Mazar, A. P. Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth Clin. Cancer Res. 2008, 14, 2137-2144
41. Cianfrocca, M. E.; Kimmel, K. A.; Gallo, J.; Cardoso, T.; Brown, M. M.; Hudes, G.; Lewis, N.; Weiner, L.; Lam, G. N.; Brown, S. C.; Shaw, D. E.; Mazar, A. P.; Cohen, R. B. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours Br. J. Cancer 2006, 94, 1621-1626
42. Zahn, G.; Vossmeyer, D.; Stragies, R.; Wills, M.; Wong, C. G.; Löffler, K. U.; Adamis, A. P.; Knolle, J. Preclinical evaluation of the novel small-molecule integrin alpha 5 beta 1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization Arch. Ophthalmol. 2009, 127, 1329-1335
43. Faerber, K.; Synowitz, M.; Zahn, G.; Vossmeyer, D.; Stragies, R.; van Rooijen, N.; Kettenmann, H. An alpha 5 beta 1 integrin inhibitor attenuates glioma growth Mol. Cell. Neurosci. 2008, 39, 579-585
44. Zhang, Y.; Yang, M.; Ji, Q.; Fan, D.; Peng, H.; Yang, C.; Xiong, D.; Zhou, Y. Anoikis induction and metastasis suppression by a new integrin αvβ3 inhibitor in human melanoma cell line M21 Invest. New Drugs 2001, 29, 666-673
45. Garrison, J. B.; Shaw, Y. J.; Chen, C. S.; Kyprianou, N. Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity Cancer Res. 2007, 67, 11344-11352
46. Giansanti, V.; Torriglia, A.; Scovassi, A. I. Conversation between apoptosis and autophagy: "Is it your turn or mine?" Apoptosis 2011, 16, 321-333
47. Tan, M. L.; Ooi, J. P.; Ismail, N.; Moad, A. I.; Muhammad, T. S. Programmed cell death pathways and current antitumor targets Pharm. Res. 2009, 26, 1547-1560
48. Levy, J. M. M.; Thorburn, A. Targeting autophagy during cancer therapy to improve clinical outcomes Pharmacol. Ther. 2011, 131, 130-141
49. Rubinsztein, D. C.; Codogno, P.; Levine, B. Autophagy modulation as a potential therapeutic target for diverse diseases Nat. Rev. Drug Discovery 2012, 11, 709-U84
50. Schenone, S.; Brullo, C.; Musumeci, F.; Radi, M.; Botta, M. ATP-competitive inhibitors of mTOR: an update Curr. Med. Chem. 2011, 18, 2995-3014
51. Babcock, J. T.; Quilliam, L. A. Rheb/mTOR activation and regulation in cancer: novel treatment strategies beyond rapamycin Curr. Drug Targets 2011, 12, 1223-1231
52. Geng, Y.; Kohli, L.; Klocke, B. J.; Roth, K. A. Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent Neuro-Oncology 2010, 12, 473-481
53. Sotelo, J.; Briceño, E.; López-González, M. A. Adding chloroquine to conventional treatment for glioblastoma multiforme-a randomized, double-blind, placebo-controlled trial Ann. Intern. Med. 2006, 144, 337-343
54. Stupp, R.; Hegi, M. E.; Mason, W. P.; Bent, M. J. V.; Taphoorn, M. J. B.; Janzer, R. C.; Ludwin, S. K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A. A.; Gijtenbeek, J.; Marosi, C.; Vecht, C. J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J. G.; Mirimanoff, R. O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 2009, 10, 459-466
55. Kanzawa, T.; Germano, I. M.; Komata, T.; Ito, H.; Kondo, Y.; Kondo, S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells Cell. Death Differ. 2004, 11, 448-457
56. Lefranc, F.; Facchini, V.; Kiss, R. Pro-autophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas Oncologist 2007, 12, 1395-1403
57. Hartford, C. M. Rapamycin: something old, something new, sometimes borrowed and now renewed Clin. Pharmacol. Ther. 2007, 82, 381-388
58. Kwitkowski, V. E.; Prowell, T, M.; Ibrahim, A.; Farrell, A. T.; Justice, R.; Mitchell, S. S.; Sridhara, R.; Pazdur, R. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma Oncologist 2010, 15, 428-435
59. Houghton, P. J. Everolimus Clin. Cancer Res. 2010, 16, 1368-1372
60. Yee, K. W.; Zeng, Z.; Konopleva, M.; Verstovsek, S.; Ravandi, F.; Ferrajoli, A.; Thomas, D.; Wierda, W.; Apostolidou, E.; Albitar, M.; O'Brien, S.; Andreeff, M.; Giles, F. J. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies Clin. Cancer Res. 2006, 12, 5165-5173
61. Voss, V.; Senft, C.; Lang, V.; Ronellenfitsch, M. W.; Steinbach, J. P.; Seifert, V.; Kögel, D. The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma Mol. Cancer Res. 2010, 8, 1002-1016
62. Lessene, G.; Czabotar, P. E.; Colman, P. M. BCL-2 family antagonists for cancer therapy Nat. Rev. Drug Discovery 2008, 7, 989-1000
63. Kang, M. H.; Reynolds, C. P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin. Cancer Res. 2009, 15, 1126-1132
64. Van Poznak, C.; Seidman, A. D.; Reidenberg, M. M.; Moasser, M. M.; Sklarin, N.; Van Zee, K.; Borgen, P.; Gollub, M.; Bacotti, D.; Yao, T. J.; Bloch, R.; Ligueros, M.; Sonenberg, M.; Norton, L.; Hudis, C. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial Breast Cancer Res. Treat. 2001, 66, 239-248
65. Brem, E. A.; Thudium, K.; Khubchandani, S.; Tsai, P. C.; Olejniczak, S. H.; Bhat, S.; Riaz, W.; Gu, J.; Iqbal, A.; Campagna, R.; Knight, J.; Mavis, C.; Hoskin, P.; Deeb, G.; Gibbs, J. F.; Fetterly, G.; Czuczman, M. S.; Hernandez-Ilizaliturri, F. J. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and-resistant lymphomas Br. J. Haematol. 2011, 153, 599-611
66. Joudeh, J.; Claxton, D. Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms Expert Opin. Invest. Drugs 2012, 21, 363-373
67. Degterev, A.; Huang, Z.; Boyce, M.; Li, Y.; Jagtap, P.; Mizushima, N.; Cuny, G. D.; Mitchison, T. J.; Moskowitz, M. A.; Yuan, J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury Nat. Chem. Biol. 2005, 1, 112-119
68. Smith, C. C. T.; Yellon, D. M. Necroptosis, necrostatins and tissue injury J. Cell. Mol. Med. 2011, 15, 1797-1806
69. Han, W.; Li, L.; Qiu, S.; Lu, Q.; Pan, Q.; Gu, Y.; Luo, J.; Hu, X. Shikonin circumvents cancer drug resistance by induction of a necroptotic death Mol. Cancer Ther. 2007, 6, 1641-1649
70. Yang, H.; Zhou, P.; Huang, H.; Chen, D.; Ma, N.; Cui, C. Q.; Shen, S.; Dong, W.; Zhang, X.; Lian, W.; Wang, X.; Dou, Q. P.; Jinbao Liu, J. Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo Int. J. Cancer 2009, 124, 2450-2459
71. Xuan, Y.; Hu, X. Naturally-occurring shikonin analogues-a class of necroptotic inducers that circumvent cancer drug resistance Cancer Lett. 2009, 274, 233-242
72. Björkhem, I.; Lütjohann, D.; Breuer, O.; Sakinis, A.; Wennmalm, Å. Importance of a novel oxidative mechanism for elimination of brain cholesterol-turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with O-18(2) techniques in vivo and in vitro J. Biol. Chem. 1997, 272, 30178-30184
73. Yamanaka, K.; Saito, Y.; Yamamori, T.; Urano, Y.; Noguchi, N. 24(S)-Hydroxycholesterol induces neuronal cell death through necroptosis, a form of programmed necrosis J. Biol. Chem. 2011, 286, 24666-24673
74. Hammerová, J.; Uldrijan, S.; Táborská, E.; Vaculová, A. H.; Slaninová, I. Necroptosis modulated by autophagy is a predominant form of melanoma cell death induced by sanguilutine Biol. Chem. 2012, 393, 647-658
75. Asare, N.; Låg, M.; Lagadic-Gossmann, D.; Rissel, M.; Schwarze, P.; Holme, J. A. 3-Nitrofluoranthene (3-NF) but not 3-aminofluoranthene (3-AF) elicits apoptosis as well as programmed necrosis in Hepa1c1c7 cells Toxicology 2009, 255, 140-150
76. Jagtap, P.; Degterev, A.; Choi, S.; Keys, H.; Yuan, J.; Cuny, G. Structure-activity relationship study of tricyclic necroptosis inhibitors J. Med. Chem. 2007, 50, 1886-1895
77. Huszar, D.; Theoclitou, M. E.; Skolnik, J.; Herbst, R. Kinesin motor proteins as targets for cancer therapy Cancer Metastasis Rev. 2009, 28, 197-208
78. Sakowicz, R.; Finer, J. T.; Beraud, C.; Crompton, A.; Lewis, E.; Fritsch, A.; Lee, Y.; Mak, J.; Moody, R.; Turincio, R.; Chabala, J. C.; Gonzales, P.; Roth, S.; Weitman, S.; Wood, K. W. Antitumor activity of a kinesin inhibitor Cancer Res. 2004, 64, 3276-3280
79. Miller, K.; Ng, C.; Ang, P.; Brufsky, A. M.; Lee, S. C.; Dees, E. C.; Piccart, M.; Verrill, M.; Wardley, A.; Loftiss, J.; Bal, J.; Yeoh, S.; Hodge, J.; Williams, D.; Dar, M.; Ho, P. T. C. Phase II, Open Label Study of SB-715992 (Ispinesib) in Subjects with Advanced or Metastatic Breast Cancer. Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 2005; Abstract 1089.
80. Kantarjian, H. M.; Padmanabhan, S.; Stock, W.; Tallman, M. S.; Curt, G. A.; Li, J.; Osmukhina, A.; Wu, K.; Huszar, D.; Borthukar, G.; Faderl, S.; Garcia-Manero, G.; Kadia, T.; Sankhala, K.; Odenike, O.; Altman, J. K.; Minden, M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia Invest. New Drugs 2012, 30, 1107-1115
81. Graves, P. R.; Yu, L.; Schwarz, J. K.; Gales, J.; Sausville, E. A.; O'Connor, P. M.; Worms, H. P. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01 J. Biol. Chem. 2000, 275, 5600-5605
82. Sarkaria, J. N.; Busby, E. C.; Tibbetts, R. S.; Roos, R.; Taya, Y.; Karnitz, L. M.; Abraham, R. T. Inhibition of ATM and ATR kinase activity by the radiosensitizing agent caffeine Cancer Res. 1999, 59, 4375-4382
83. Zhao, H.; Watkins, J. L.; Helen Piwnica-Worms, H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 14795-14800
84. Ma, C. X.; Janetka, J. W.; Piwnica, W. H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics Trends Mol. Med. 2011, 17, 88-96
85. Zabludoff, S. D.; Deng, C.; Grondine, M. R.; Sheehy, A. M.; Ashwell, S.; Caleb, B. L.; Green, S.; Haye, H. R.; Horn, C. L.; Janetka, J. W.; Liu, D.; Mouchet, E.; Ready, S.; Rosenthal, J. L.; Queva, C.; Schwartz, G. K.; Taylor, K. J.; Tse, A. N.; Walker, G. E.; White, A. M. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA targeted therapies Mol. Cancer Ther. 2008, 7, 2955-2966
86. Mitchell, J. B.; Choudhuri, R.; Fabre, K.; Sowers, A. L.; Citrin, D.; Zabludoff, S. D.; Cook, J. A. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor. AZD7762 Clin. Cancer Res. 2010, 16, 2076-2084
87. Morgan, M. A.; Parsels, L. A.; Zha, L.; Parsels, J. D.; Davis, M. A.; Hassan, M. C.; Arumugarajah, S.; Hylander-Gans, L.; Morosini, D.; Simeone, D. M.; Canman, C. E.; Normolle, D. P.; Zabludoff, S. D.; Maybaum, J.; Lawrence, T. S. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair Cancer Res. 2010, 70, 4972-4981
88. Blasina, A.; Hallin, J.; Chen, E.; Arango, M. E.; Kraynov, E.; Register, J.; Grant, S.; Ninkovic, S.; Chen, P.; Nichols, T.; O'Connor, P.; Anderes, K. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase Mol. Cancer Ther. 2008, 7, 2394-2404
89. Guzi, T. J.; Paruch, K.; Dwyer, M. P.; Labroli, M.; Shanahan, F.; Davis, N.; Taricani, L.; Wiswell, D.; Seghezzi, W.; Penaflor, E.; Bhagwat, B.; Wang, W.; Gu, D. L.; Hsieh, Y. S.; Lee, S.; Liu, M.; Parry, D. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening Mol. Cancer Ther. 2011, 10, 591-602
90. Purcell, J. W.; Reddy, M.; Davis, J.; Samayoa, K.; Vo, C. H.; Thomsen, K.; Bean, P. A.; Wood, K. W.; Cases, S. Ispinesib (SB-715992) a kinesin spindle protein (KSP) inhibitor has single agent activity and enhances the efficacy of standard-of-care therapies in pre-clinical models of breast cancer Cancer Res. 2009, 69, 193S-193S
91. Blagden, S.; de Bono, J. Drugging cell cycle kinases in cancer therapy Curr. Drug Targets 2005, 6, 325-335
92. Kortmansky, J.; Shah, M. A.; Kaubisch, A.; Weyerbacher, A.; Yi, S.; Tong, W.; Sowers, R.; Gonen, M.; O'Reilly, E.; Kemeny, N.; Ilson, D. I.; Saltz, L. B.; Maki, R. G.; Kelsen, D. P.; Schwartz, G. K. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors J. Clin. Oncol. 2005, 23, 1875-1884
93. Brega, N.; McArthur, G. A.; Britten, C.; Wong, S. G.; Wang, E.; Wilner, K. D.; Blasina, A.; Schwartz, G. K.; Gallo, J.; Tse, A. N. Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase J. Clin. Oncol. 2010, 28 (Suppl.) 3062
94. Daud, A.; Springett, G. M.; Mendelson, D. S.; aMunster, P. N.; Goldman, J. W.; Strosberg, J. R.; Kato, G.; Nesheiwat, T.; Isaacs, R.; Rosen, L. S. A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors J. Clin. Oncol. 2010, 28, 3064
95. Karp, J. E.; Thomas, B. M.; Greer, J. M.; Sorge, C.; Gore, S. D.; Pratz, K. W.; Smith, B. D.; Flatten, K. S.; Peterson, K.; Schneider, P.; Mackey, K.; Freshwater, T.; Levis, M. J.; McDevitt, M. A.; Carraway, H. E.; Gladstone, D. E.; Showel, M. M.; Loechner, S.; Parry, D. A.; Horowitz, D. A.; Isaacs, R.; Kaufmann, S. H. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias Clin. Cancer Res. 2012, 18, 6723-6731
96. Hyzy, M.; Bozko, P.; Konopa, J.; Skladanowski, A. Antitumour imidazoacridone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells Biochem. Pharmacol. 2005, 69, 801-809
97. Chen, Y. W.; Chen, Y. L.; Tseng, C. H.; Liang, C. C.; Yang, C. N.; Yao, Y. C.; Lu, P. J.; Tzeng, C. C. Discovery of 4-anilinofuro[2,3- b ]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers J. Med. Chem. 2011, 54, 4446-4461
98. Sperandio, S.; Belle, I. D.; Bredesen, D. E. An alternative, nonapoptotic form of programmed cell death Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 14376-14381
99. Mariela Palmeri, C.; Pablo, P. J.; Liliana, D. V. S.; Silvina, G.; Lucía, D. P. A.; Humberto, M. J.; Inés, T. A. Bromocriptine induces parapoptosis as the main type of cell death responsible for experimental pituitary tumor shrinkage Toxicol. Appl. Pharmacol. 2009, 240, 55-65
100. Zhang, J. S.; Li, D. M.; He, N.; Liu, Y. H.; Wang, C. H.; Jiang, S. Q.; Chen, B. Q.; Liu, J. R. A paraptosis-like cell death induced by delta-tocotrienol in human colon carcinoma SW620 cells is associated with the suppression of the Wnt signaling pathway Toxicology 2011, 285, 8-17
101. Musende, A. G.; Eberding, A.; Wood, C.; Adomat, H.; Fazli, L.; Hurtado-Coll, A.; Jia, W.; Bally, M. B.; Guns, E. T. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy Cancer Chemother. Pharmacol. 2009, 64, 1085-1095
102. Li, B.; Zhao, J.; Wang, C. Z.; Searle, J.; He, T. C.; Yuan, C. S.; Du, W. Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53 Cancer Lett. 2011, 301, 185-192
103. Fried, L. E.; Arbiser, J. L. Honokiol, a multifunctional antiangiogenic and antitumor agent Antioxid. Redox Signaling 2009, 11, 1139-1148
104. Xu, H. L.; Tang, W.; Du, G. H.; Kokudo, N. Targeting apoptosis pathways in cancer with magnolol and honokiol, bioactive constituents of the bark of Magnolia officinalis Drug Discovery Ther. 2011, 5, 202-210
105. Wang, Y.; Yang, Z.; Zhao, X. Honokiol induces paraptosis and apoptosis and exhibits schedule-dependent synergy in combination with imatinib in human leukemia cells Toxicol. Mech. Methods 2010, 20, 234-241
106. Samadder, P.; Bittman, R.; Byun, H. S.; Arthur, G. A glycosylated antitumor ether lipid kills cells via paraptosis-like cell death Biochem. Cell Biol. 2009, 87, 401-414
107. Korsnes, M. S.; Espenes, A.; Hetland, D. L.; Hermansen, L. C. Paraptosis-like cell death induced by yessotoxin Toxicol. in Vitro 2011, 25, 1764-1770
108. Korsnes, M. S. Yessotoxin as a tool to study induction of multiple cell death pathways Toxins 2012, 4, 568-579
109. Ame, J. C.; Spemlehauer, C.; de Murcia, G. The PARP superfamily BioEssays 2004, 26, 882-893
110. Pishvaian, M. J; Slack, R.; Witkiewicz, A.; He, A. R.; Hwang, J. J.; Hankin, A.; Dorsch-Vogel, K.; Kuda, D.; McAndrew, T.; Weiner, L. M.; Marshall, J.; Brody, J. R. A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer J. Clin. Oncol. 2011, 29 (Suppl.) 3502
111. Davar, D.; Beumer, J. H.; Hamieh, L.; Tawbi, H. Role of PARP inhibitors in cancer biology and therapy Curr. Med. Chem. 2012, 19, 3907-3921
112. Ferraris, D. V. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic J. Med. Chem. 2010, 53, 4561-4584
113. Chiu, L. Y.; Ho, F. M.; Shiah, S. G.; Chang, Y.; Lin, W. W. Oxidative stress initiates DNA damager MNNG-induced poly(ADP-ribose)polymerase-1-dependent parthanatos cell death Biochem. Pharmacol. 2011, 81, 459-470
114. Plummer, R. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM) J. Clin. Oncol 2006, 24 (Suppl.) 8013
115. Drew, Y.; Ledermann, J. A; Jones, A.; Hall, G.; Jayson, G. C.; Highley, M.; Rea, D.; Glasspool, R. M.; Halford, S. E. R.; Crosswell, G.; Colebrook, S.; Boddy, A. V.; Curtin, N. J.; Plummer, E. R. Phase II trial of the poly(ADPribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer J. Clin. Oncol. 2011, 29 (Suppl.) 3104
116. Overmeyer, J. H.; Kaul, A.; Johnson, E. E.; Maltese, W. A. Active Ras triggers death in glioblastoma cells through hyperstimulation of macropinocytosis Mol. Cancer Res. 2008, 6, 965-977
117. Bhanot, H.; Young, A. M.; Overmeyer, J. H.; Maltese, W. A. Induction of nonapoptotic cell death by activated Ras requires inverse regulation of Rac1 and Arf6 Mol. Cancer Res. 2010, 8, 1358-1374
118. Robinson, M. W.; Overmeyer, J. H.; Young, A. M.; Erhardt, P. W.; Maltese, W. A. Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel type of nonapoptotic cell death J. Med. Chem. 2012, 55, 1940-1956
119. Annereau, J. P.; Brel, V.; Dumontet, C.; Guminski, Y.; Imbert, T.; Broussas, M.; Vispe, S.; Breand, S.; Guilbaud, N.; Barret, J. M.; Bailly, C. A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment Leuk. Res. 2010, 34, 1383-1389
120. Kruczynski, A.; Vandenberghe, I.; Pillon, A.; Pesnel, S.; Goetsch, L.; Barret, J. M.; Guminski, Y.; Le, P. A.; Imbert, T.; Bailly, C.; Guilbaud, N. Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system Invest. New Drugs 2011, 29, 9-21
121. Brel, V.; Annereau, J. P.; Vispé, S.; Kruczynski, A.; Bailly, C.; Guilbaud, N. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II Biochem. Pharmacol. 2011, 82, 1843-1852
122. Dunn, W. A., Jr. Studies on the mechanisms of autophagy: formation of the autophagic vacuole J. Cell Biol. 1990, 110, 1923-1933
123. Suarez, Y.; Gonzalez, L.; Cuadrado, A.; Berciano, M.; Lafarga, M.; Munoz, A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells Mol. Cancer Ther. 2003, 2, 863-872
124. Shilabin, A. G.; Shilabin, A. G.; Kasanah, N.; Wedge, D. E.; Hamann, M. T. Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies J. Med. Chem. 2007, 50, 4340-4350
125. Gao, J.; Hamann, M. T. Chemistry and biology of kahalalides Chem. Rev. 2011, 111, 3208-3235
126. Weerasinghe, P.; Buja, L. M. Oncosis: an important non-apoptotic mode of cell death Exp. Mol. Pathol. 2012, 93, 302-308
127. Trump, B. E.; Berezesky, I. K.; Chang, S. H.; Phelps, P. C. The pathway of cell death: oncosis, apoptosis and necrosis Toxicol. Pathol. 1997, 25, 82-88
128. Martín-Algarra, S.; Espinosa, E.; Rubió, J.; López López, J. J.; Manzano, J. L.; Carrión, L. A.; Plazaola, A.; Tanovic, A.; Paz-Ares, L. Phase II study of weekly kahalalide F in patients with advanced malignant melanoma Eur. J. Cancer 2009, 45, 732-735
129. Berndt, C.; Kurz, T.; Bannenberg, S.; Jacob, R.; Holmgren, A.; Brunk, U. T. Ascorbate and endocytosed motexafin gadolinium induce lysosomal rupture Cancer Lett. 2011, 307, 119-123
130. McHaffie, D. R.; Chabot, P.; Dagnault, A.; Suh, J. H.; Fortin, M. A.; Chang, E.; Timmerman, R.; Souhami, L.; Grecula, J.; Nabid, A.; Schultz, C.; Werner-Wasik, M.; Gaspar, L. E.; Brachman, D.; Mody, T.; Mehta, M. P. Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of brain metastases: a multi-institutional phase II trial J. Neuro-Oncol. 2011, 105, 301-308
131. Venè, R.; Arena, G.; Poggi, A.; D'Arrigo.; Mormino, M.; Noonan, D. M.; Albini, A.; Tosetti, F. Novel cell death pathways induced by N -(4-hydroxyphenyl)retinamide: therapeutic implications Mol. Cancer Ther. 2007, 6, 286-298
132. Puduvalli, V. K.; Alfred Yung, W. K.; Hess, K. R.; Kuhn, J. G.; Groves, M. D.; Levin, V. A.; Zwiebel, J.; Chang, S. M.; Cloughesy, T. F.; Junck, L.; Wen, P.; Lieberman, F.; Conrad, C. A; Gilbert, M. R.; Meyers, C. A.; Liu, V.; Mehta, M. P.; Nicholas, K. M.; Prados, M. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: a North American brain tumor consortium study J. Clin. Oncol. 2004, 22, 4282-4289
133. Ostenfeld, M. S.; Høyer-Hansen, M.; Bastholm, L.; Fehrenbacher, N.; Olsen, O. D.; Groth-Pedersen, L.; Puustinen, P.; Kirkegaard-Sørensen, T.; Nylandsted, J.; Farkas, T.; Jäättelä, M. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation Autophagy 2008, 4, 487-499
134. Ostenfeld, M. S.; Fehrenbacher, N.; Høyer-Hansen, M.; Thomsen, C.; Farkas, T.; Jäättelä, M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress Cancer Res. 2005, 65, 8975-8983
135. Barbosa, C. M. V.; Oliveira, C. R.; Nascimento, F. D.; Smith, M. C. M.; Fausto, D. M.; Soufen, M. A.; Sena, E.; Araújo, R. C.; Tersariol, I. L. S.; Bincoletto, C.; Caires, A. C. F. Biphosphinic palladacycle complex mediates lysosomal-membrane permeabilization and cell death in K562 leukaemia cells Eur. J. Pharmacol. 2006, 542, 37-47
136. Du, J. H.; Zhang, H. De; Ma, Z. J.; Ji, K. M. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo Cancer Chemother. Pharmacol. 2010, 65, 895-902
137. Sun, L.; Zhao, Y.; Yuan, H.; Li, X.; Cheng, A.; Lou, H. Solamargine, a steroidal alkaloid glycoside, induces oncosis in human K562 leukemia and squamous cell carcinoma KB cells Cancer Chemother. Pharmacol. 2011, 67, 813-821